Pretreatment with nafamostat mesilate, a kallikrein inhibitor, to decrease withdrawal response associated with rocuronium
Purpose This randomized, double-blind, placebo-controlled study was conducted to examine the preventive effect of nafamostat mesilate, a kallikrein inhibitor, on the withdrawal response associated with rocuronium injection. Methods Ninety American Society of Anesthesiology (ASA) physical status I or...
Gespeichert in:
| Veröffentlicht in: | Journal of anesthesia 2010-08, Vol.24 (4), p.549-552 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 552 |
|---|---|
| container_issue | 4 |
| container_start_page | 549 |
| container_title | Journal of anesthesia |
| container_volume | 24 |
| creator | Kim, Yoon Hee Go, Young Kwon Lee, Jung Un Chung, Woo Suk Shin, Yong Sup Han, Kyu Cheol Shin, Ji Eun Lee, Suk Hoon |
| description | Purpose
This randomized, double-blind, placebo-controlled study was conducted to examine the preventive effect of nafamostat mesilate, a kallikrein inhibitor, on the withdrawal response associated with rocuronium injection.
Methods
Ninety American Society of Anesthesiology (ASA) physical status I or II patients, aged 18–65 years, were randomly divided into two groups that received either a 1.5-ml solution containing 1.5 mg nafamostat mesilate diluted in a 5% glucose solution or a 1.5-ml 5% glucose solution. Anesthesia was induced by 5 mg/kg 2.5% thiopental. After confirming loss of consciousness, a tourniquet was applied to the mid forearm and tightened to block venous flow. The test solution was then administered, 1 min after which the tourniquet was removed and 0.6 mg/kg rocuronium was administered. Each patient’s response to rocuronium injection was graded on a four-point scale in a double-blind manner. Activated coagulation time and plasma potassium concentration were measured before and 5 and 10 min after nafamostat administration.
Results
The incidence of withdrawal response was 68.9% in the control group and 24.4% in the nafamostat group (
P
|
| doi_str_mv | 10.1007/s00540-010-0964-8 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A356142177</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A356142177</galeid><sourcerecordid>A356142177</sourcerecordid><originalsourceid>FETCH-LOGICAL-c501t-7f7b59ffd93d6a3620af492958055c44d2d4d09d03613465919441bb8abee6383</originalsourceid><addsrcrecordid>eNp9kV1rHCEUhqU0NNu0P6A3RehtJtHxY8bLENIPCLQX6bU4etyYzOiiLiH_vm6mLRSWIiIcn-dFfBH6QMkFJWS4LIQITjpC21aSd-MrtKGcjd3IhHqNNkRR1o1SjqfobSkPhBBJKXuDTnvCleqF2KDnHxlqBlMXiBU_hXqPo_FmSaWaihcoYTYVzrHBj2aew2OGEHGI92EKNeVzXBN2YFtAgRfbZfNkZpyh7FJsM1NKsqFFuDU8J7vPKYb98g6deDMXeP_7PEM_P9_cXX_tbr9_-XZ9ddtZQWjtBj9MQnnvFHPSMNkT47nqlRiJEJZz1zvuiHKEScq4FIoqzuk0jWYCkGxkZ-jTmrs1M-gQfarZ2CUUq6-YkJT3dBga1R2hthAhmzlF8KGN_-EvjvBtOViCPSrQVbA5lZLB610Oi8nPmhJ9aFOvberWpj60qQ9P_7g6u_20gPtr_KmvAf0KlHYVt5D1Q9rn2L7zP6m_AFDZqsg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pretreatment with nafamostat mesilate, a kallikrein inhibitor, to decrease withdrawal response associated with rocuronium</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kim, Yoon Hee ; Go, Young Kwon ; Lee, Jung Un ; Chung, Woo Suk ; Shin, Yong Sup ; Han, Kyu Cheol ; Shin, Ji Eun ; Lee, Suk Hoon</creator><creatorcontrib>Kim, Yoon Hee ; Go, Young Kwon ; Lee, Jung Un ; Chung, Woo Suk ; Shin, Yong Sup ; Han, Kyu Cheol ; Shin, Ji Eun ; Lee, Suk Hoon</creatorcontrib><description>Purpose
This randomized, double-blind, placebo-controlled study was conducted to examine the preventive effect of nafamostat mesilate, a kallikrein inhibitor, on the withdrawal response associated with rocuronium injection.
Methods
Ninety American Society of Anesthesiology (ASA) physical status I or II patients, aged 18–65 years, were randomly divided into two groups that received either a 1.5-ml solution containing 1.5 mg nafamostat mesilate diluted in a 5% glucose solution or a 1.5-ml 5% glucose solution. Anesthesia was induced by 5 mg/kg 2.5% thiopental. After confirming loss of consciousness, a tourniquet was applied to the mid forearm and tightened to block venous flow. The test solution was then administered, 1 min after which the tourniquet was removed and 0.6 mg/kg rocuronium was administered. Each patient’s response to rocuronium injection was graded on a four-point scale in a double-blind manner. Activated coagulation time and plasma potassium concentration were measured before and 5 and 10 min after nafamostat administration.
Results
The incidence of withdrawal response was 68.9% in the control group and 24.4% in the nafamostat group (
P
< 0.001). The number of patients showing generalized movement (response 4) with the rocuronium injection was significantly lower in nafamostat group [1 (2.2%)] than the control group [15 (33.3%)],
P
< 0.001. Five and 10 min after nafamostat administration, measured potassium and activated coagulation time were similar to baseline values.
Conclusion
Pretreatment with 1.5 mg nafamostat mesilate decreased withdrawal response associated with rocuronium injection.</description><identifier>ISSN: 0913-8668</identifier><identifier>EISSN: 1438-8359</identifier><identifier>DOI: 10.1007/s00540-010-0964-8</identifier><identifier>PMID: 20499255</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Adult ; Androstanols - adverse effects ; Anesthesia ; Anesthesiology ; Critical Care Medicine ; Dextrose ; Double-Blind Method ; Emergency Medicine ; Female ; Glucose ; Glucose metabolism ; Guanidines - pharmacology ; Humans ; Intensive ; Kallikrein ; Kallikreins - antagonists & inhibitors ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neuromuscular blocking agents ; Neuromuscular Nondepolarizing Agents - adverse effects ; Original Article ; Pain Medicine</subject><ispartof>Journal of anesthesia, 2010-08, Vol.24 (4), p.549-552</ispartof><rights>Japanese Society of Anesthesiologists 2010</rights><rights>COPYRIGHT 2010 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c501t-7f7b59ffd93d6a3620af492958055c44d2d4d09d03613465919441bb8abee6383</citedby><cites>FETCH-LOGICAL-c501t-7f7b59ffd93d6a3620af492958055c44d2d4d09d03613465919441bb8abee6383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00540-010-0964-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00540-010-0964-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20499255$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Yoon Hee</creatorcontrib><creatorcontrib>Go, Young Kwon</creatorcontrib><creatorcontrib>Lee, Jung Un</creatorcontrib><creatorcontrib>Chung, Woo Suk</creatorcontrib><creatorcontrib>Shin, Yong Sup</creatorcontrib><creatorcontrib>Han, Kyu Cheol</creatorcontrib><creatorcontrib>Shin, Ji Eun</creatorcontrib><creatorcontrib>Lee, Suk Hoon</creatorcontrib><title>Pretreatment with nafamostat mesilate, a kallikrein inhibitor, to decrease withdrawal response associated with rocuronium</title><title>Journal of anesthesia</title><addtitle>J Anesth</addtitle><addtitle>J Anesth</addtitle><description>Purpose
This randomized, double-blind, placebo-controlled study was conducted to examine the preventive effect of nafamostat mesilate, a kallikrein inhibitor, on the withdrawal response associated with rocuronium injection.
Methods
Ninety American Society of Anesthesiology (ASA) physical status I or II patients, aged 18–65 years, were randomly divided into two groups that received either a 1.5-ml solution containing 1.5 mg nafamostat mesilate diluted in a 5% glucose solution or a 1.5-ml 5% glucose solution. Anesthesia was induced by 5 mg/kg 2.5% thiopental. After confirming loss of consciousness, a tourniquet was applied to the mid forearm and tightened to block venous flow. The test solution was then administered, 1 min after which the tourniquet was removed and 0.6 mg/kg rocuronium was administered. Each patient’s response to rocuronium injection was graded on a four-point scale in a double-blind manner. Activated coagulation time and plasma potassium concentration were measured before and 5 and 10 min after nafamostat administration.
Results
The incidence of withdrawal response was 68.9% in the control group and 24.4% in the nafamostat group (
P
< 0.001). The number of patients showing generalized movement (response 4) with the rocuronium injection was significantly lower in nafamostat group [1 (2.2%)] than the control group [15 (33.3%)],
P
< 0.001. Five and 10 min after nafamostat administration, measured potassium and activated coagulation time were similar to baseline values.
Conclusion
Pretreatment with 1.5 mg nafamostat mesilate decreased withdrawal response associated with rocuronium injection.</description><subject>Adult</subject><subject>Androstanols - adverse effects</subject><subject>Anesthesia</subject><subject>Anesthesiology</subject><subject>Critical Care Medicine</subject><subject>Dextrose</subject><subject>Double-Blind Method</subject><subject>Emergency Medicine</subject><subject>Female</subject><subject>Glucose</subject><subject>Glucose metabolism</subject><subject>Guanidines - pharmacology</subject><subject>Humans</subject><subject>Intensive</subject><subject>Kallikrein</subject><subject>Kallikreins - antagonists & inhibitors</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neuromuscular blocking agents</subject><subject>Neuromuscular Nondepolarizing Agents - adverse effects</subject><subject>Original Article</subject><subject>Pain Medicine</subject><issn>0913-8668</issn><issn>1438-8359</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kV1rHCEUhqU0NNu0P6A3RehtJtHxY8bLENIPCLQX6bU4etyYzOiiLiH_vm6mLRSWIiIcn-dFfBH6QMkFJWS4LIQITjpC21aSd-MrtKGcjd3IhHqNNkRR1o1SjqfobSkPhBBJKXuDTnvCleqF2KDnHxlqBlMXiBU_hXqPo_FmSaWaihcoYTYVzrHBj2aew2OGEHGI92EKNeVzXBN2YFtAgRfbZfNkZpyh7FJsM1NKsqFFuDU8J7vPKYb98g6deDMXeP_7PEM_P9_cXX_tbr9_-XZ9ddtZQWjtBj9MQnnvFHPSMNkT47nqlRiJEJZz1zvuiHKEScq4FIoqzuk0jWYCkGxkZ-jTmrs1M-gQfarZ2CUUq6-YkJT3dBga1R2hthAhmzlF8KGN_-EvjvBtOViCPSrQVbA5lZLB610Oi8nPmhJ9aFOvberWpj60qQ9P_7g6u_20gPtr_KmvAf0KlHYVt5D1Q9rn2L7zP6m_AFDZqsg</recordid><startdate>20100801</startdate><enddate>20100801</enddate><creator>Kim, Yoon Hee</creator><creator>Go, Young Kwon</creator><creator>Lee, Jung Un</creator><creator>Chung, Woo Suk</creator><creator>Shin, Yong Sup</creator><creator>Han, Kyu Cheol</creator><creator>Shin, Ji Eun</creator><creator>Lee, Suk Hoon</creator><general>Springer Japan</general><general>Springer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20100801</creationdate><title>Pretreatment with nafamostat mesilate, a kallikrein inhibitor, to decrease withdrawal response associated with rocuronium</title><author>Kim, Yoon Hee ; Go, Young Kwon ; Lee, Jung Un ; Chung, Woo Suk ; Shin, Yong Sup ; Han, Kyu Cheol ; Shin, Ji Eun ; Lee, Suk Hoon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c501t-7f7b59ffd93d6a3620af492958055c44d2d4d09d03613465919441bb8abee6383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Androstanols - adverse effects</topic><topic>Anesthesia</topic><topic>Anesthesiology</topic><topic>Critical Care Medicine</topic><topic>Dextrose</topic><topic>Double-Blind Method</topic><topic>Emergency Medicine</topic><topic>Female</topic><topic>Glucose</topic><topic>Glucose metabolism</topic><topic>Guanidines - pharmacology</topic><topic>Humans</topic><topic>Intensive</topic><topic>Kallikrein</topic><topic>Kallikreins - antagonists & inhibitors</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neuromuscular blocking agents</topic><topic>Neuromuscular Nondepolarizing Agents - adverse effects</topic><topic>Original Article</topic><topic>Pain Medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Yoon Hee</creatorcontrib><creatorcontrib>Go, Young Kwon</creatorcontrib><creatorcontrib>Lee, Jung Un</creatorcontrib><creatorcontrib>Chung, Woo Suk</creatorcontrib><creatorcontrib>Shin, Yong Sup</creatorcontrib><creatorcontrib>Han, Kyu Cheol</creatorcontrib><creatorcontrib>Shin, Ji Eun</creatorcontrib><creatorcontrib>Lee, Suk Hoon</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of anesthesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Yoon Hee</au><au>Go, Young Kwon</au><au>Lee, Jung Un</au><au>Chung, Woo Suk</au><au>Shin, Yong Sup</au><au>Han, Kyu Cheol</au><au>Shin, Ji Eun</au><au>Lee, Suk Hoon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pretreatment with nafamostat mesilate, a kallikrein inhibitor, to decrease withdrawal response associated with rocuronium</atitle><jtitle>Journal of anesthesia</jtitle><stitle>J Anesth</stitle><addtitle>J Anesth</addtitle><date>2010-08-01</date><risdate>2010</risdate><volume>24</volume><issue>4</issue><spage>549</spage><epage>552</epage><pages>549-552</pages><issn>0913-8668</issn><eissn>1438-8359</eissn><abstract>Purpose
This randomized, double-blind, placebo-controlled study was conducted to examine the preventive effect of nafamostat mesilate, a kallikrein inhibitor, on the withdrawal response associated with rocuronium injection.
Methods
Ninety American Society of Anesthesiology (ASA) physical status I or II patients, aged 18–65 years, were randomly divided into two groups that received either a 1.5-ml solution containing 1.5 mg nafamostat mesilate diluted in a 5% glucose solution or a 1.5-ml 5% glucose solution. Anesthesia was induced by 5 mg/kg 2.5% thiopental. After confirming loss of consciousness, a tourniquet was applied to the mid forearm and tightened to block venous flow. The test solution was then administered, 1 min after which the tourniquet was removed and 0.6 mg/kg rocuronium was administered. Each patient’s response to rocuronium injection was graded on a four-point scale in a double-blind manner. Activated coagulation time and plasma potassium concentration were measured before and 5 and 10 min after nafamostat administration.
Results
The incidence of withdrawal response was 68.9% in the control group and 24.4% in the nafamostat group (
P
< 0.001). The number of patients showing generalized movement (response 4) with the rocuronium injection was significantly lower in nafamostat group [1 (2.2%)] than the control group [15 (33.3%)],
P
< 0.001. Five and 10 min after nafamostat administration, measured potassium and activated coagulation time were similar to baseline values.
Conclusion
Pretreatment with 1.5 mg nafamostat mesilate decreased withdrawal response associated with rocuronium injection.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>20499255</pmid><doi>10.1007/s00540-010-0964-8</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0913-8668 |
| ispartof | Journal of anesthesia, 2010-08, Vol.24 (4), p.549-552 |
| issn | 0913-8668 1438-8359 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A356142177 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Androstanols - adverse effects Anesthesia Anesthesiology Critical Care Medicine Dextrose Double-Blind Method Emergency Medicine Female Glucose Glucose metabolism Guanidines - pharmacology Humans Intensive Kallikrein Kallikreins - antagonists & inhibitors Male Medicine Medicine & Public Health Middle Aged Neuromuscular blocking agents Neuromuscular Nondepolarizing Agents - adverse effects Original Article Pain Medicine |
| title | Pretreatment with nafamostat mesilate, a kallikrein inhibitor, to decrease withdrawal response associated with rocuronium |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T19%3A03%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pretreatment%20with%20nafamostat%20mesilate,%20a%20kallikrein%20inhibitor,%20to%20decrease%20withdrawal%20response%20associated%20with%20rocuronium&rft.jtitle=Journal%20of%20anesthesia&rft.au=Kim,%20Yoon%20Hee&rft.date=2010-08-01&rft.volume=24&rft.issue=4&rft.spage=549&rft.epage=552&rft.pages=549-552&rft.issn=0913-8668&rft.eissn=1438-8359&rft_id=info:doi/10.1007/s00540-010-0964-8&rft_dat=%3Cgale_cross%3EA356142177%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/20499255&rft_galeid=A356142177&rfr_iscdi=true |